Research
Novel ADC Boosts Survival in Pretreated Endometrial Cancer
The Brief
- Results from the TroFuse-005 trial were presented at the annual ESMO congress.
- The investigational antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) significantly improved survival in pretreated endometrial cancer, according to the trial results.
Why it matters
It reports a survival benefit from an investigational drug in a patient group with limited treatment options after prior therapy, which may inform future endometrial cancer treatment research.
Who’s affected
- oncologists and patients with pretreated endometrial cancer
- #oncology
- #endometrial cancer
- #antibody-drug conjugate
- #clinical trial
- #sacituzumab tirumotecan
(MedPage Today) -- Results from the TroFuse-005 trial presented at the annual European Society for Medical Oncology congress showed that the investigational antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) significantly improved...